NEW YORK (GenomeWeb) – Quest Diagnostics reported Thursday that its first quarter revenues grew around 1 percent from the previous year and beat analysts' consensus estimate.

For the three months ended March 31, Quest reported $1.86 billion in revenues compared to $1.84 billion for the first quarter in 2015 and exceeding Wall Street's expectation of $1.82 billion.

On an equivalent basis, excluding Q1 2015 revenues from the firm's clinical trials testing business that is now part of the Q2 Solutions joint venture, revenue growth was nearly 4 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.